

Entod unveils losartan eye drops to redefine the future of corneal healing and vision restoration

Entod Pharmaceuticals, one of India's leading and fastest growing ophthalmic specialty pharmaceutical companies, has announced a significant global milestone in eye care therapeutics with the successful development of the world's first losartan ophthalmic formulation for managing corneal wound scarring — a major cause of preventable vision loss worldwide.

Losartan, widely known as an oral antihypertensive agent, has recently shown strong anti-fibrotic and anti-scarring activity in corneal tissue, supported by published international research. Entod's R&D team has successfully repurposed and stabilized this molecule into a topical ophthalmic eye drop formulation at its DSIR approved R&D centre in Navi Mumbai. Developed using the company's proprietary EyeBS advanced ionic buffer technology, this represents a global first in ophthalmic formulation science.

This innovation underscores Entod's expertise in ocular drug delivery, advanced formulation design, and safer preservative systems, reaffirming its long-standing commitment to addressing unmet needs in ophthalmology, said the communication note.

The company said it will soon commence the formal drug regulatory pathway in India, with clinical trials planned for early 2026 to evaluate safety, efficacy, and long-term outcomes. The process includes obtaining approval from the Central Drugs Standard Control Organization (CDSCO) to initiate trials, followed by seeking Drug Controller General of India (DCGI) approval for commercialization. The product will be marketed under the trademark OcuZart, available by prescription only.

Dr K V Satyamurthy, senior consultant, M M Joshi Eye Institute, Dharwad said: "Corneal scarring caused by trauma, infections, or post-surgical complications remains one of the leading causes of irreversible vision loss. Current treatments are limited, slow, and often invasive. India accounts for a large proportion of global cases due to high rates of ocular trauma, agricultural injuries, infectious keratitis, and delayed access to care. Entod's losartan eye drops, once approved, could significantly reduce corneal fibrosis, enhance corneal clarity, and improve visual rehabilitation — marking a long-awaited pharmacological advance in this domain."

Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, stated: "Corneal scarring affects millions, yet therapeutic progress has been stagnant. These eye drops have the potential to transform how ophthalmologists manage corneal healing and vision restoration. We are proud to reinforce India's leadership in ophthalmic research, formulation science, and patient centric innovation."

With over 48 years of expertise and more than 200 commercialized eye care products, Entod continues to drive breakthroughs across myopia control, presbyopia management, dry eye therapy, and surgical ophthalmology. This development reinforces Entod's mission to position India at the forefront of global ophthalmic R&D and specialty formulations. In the last 18 months, Entod has also successfully launched India's first eye drops for presbyopia and a world first ophthalmic therapy for myopia in children — further expanding its legacy of world leading innovations, said the communication note.

News Source:

<https://www.pharmabiz.com/NewsDetails.aspx?aid=183579&sid=2>